Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 4 Myelodysplastic Syndromes 2 Melanoma 2 Uveal Melanoma 1 Recurrence 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Head and Neck Neoplasms 1 Disease Progression 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Cetuximab 44 Oxaliplatin 39 Irinotecan 38 Fluorouracil 36 Capecitabine 36 Bevacizumab 36 pembrolizumab 35 Leucovorin 34 Nivolumab 21 Gemcitabine 17 regorafenib 13 Panitumumab 12 IFL protocol 12 Folfox protocol 12 Cyclophosphamide 12 Pemetrexed 11 Cisplatin 11 tislelizumab 9 Paclitaxel 9 HMPL-013 9 Carboplatin 9 130-nm albumin-bound paclitaxel 8 durvalumab 7 Specimen Handling 7 Docetaxel 7 trametinib 6 Trifluridine 6 Ipilimumab 6 Drug Therapy 6 trifluridine tipiracil drug combination 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Colorectal Neoplasms × Valproic Acid × Clear all

NCT01898104 2023-03-24

V-shoRT-R3

National Cancer Institute, Naples

Phase 1/2 Unknown

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡